AIDS News and Research

RSS

BC-CfE study suggests HAART may prevent transmission, spread of HIV

The BC Centre of Excellence in HIV/AIDS published an important study today in the globally respected Lancet medical journal. The study strongly reinforces the view that the benefits of highly active antiretroviral therapy extend beyond treatment of the virus to significantly preventing the transmission and spread of HIV.

20 Jul 2010

Cash rewards help combat STIs in rural Africa, study finds

Giving out cash can be an effective tool in combating sexually transmitted infections in rural Africa, according to a new study conducted jointly by researchers at the University of California, Berkeley, the Development Research Group at the World Bank and the Ifakara Health Institute in Tanzania.

20 Jul 2010

AIDS 2010 studies, releases: Treating HIV-positive patients with ARVs drove down number of new HIV infections, study finds

"Treating HIV patients with cocktails of AIDS drugs helps to stop them spreading the infection further and more than halved the number of new HIV diagnoses in a study in Canada, scientists said on Sunday," Reuters reports.

20 Jul 2010

International organizations mutually agree to eradicate pediatric HIV/AIDS by 2015

A global alliance of international organizations, including the heads of UNICEF, UNAIDS and The Global Fund to Fight AIDS, Tuberculosis and Malaria as well as other NGOs including the Pan African Treatment Access Movement, Health GAP, Ugandan Pediatric Association and the Global AIDS Alliance today agreed to take concerted action to eliminate pediatric HIV/AIDS over the next five years, preventing nearly 400,000 children annually from beginning their lives infected with the virus that causes AIDS.

20 Jul 2010

New microbicide gel reduces woman's risk of being infected with HIV, genital herpes

Today at the XVIII International AIDS Conference in Vienna, Austria, members of the International Rectal Microbicide Advocates (IRMA) and thousands of other HIV advocates and scientists cheered a long-awaited, much anticipated success in the quest for new HIV prevention technologies. Researchers announced that a vaginal gel has been shown to significantly reduce a woman's risk of being infected with HIV and genital herpes

20 Jul 2010

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.

20 Jul 2010

Infants in African countries receive minimum help to reduce risk of mother-to-child HIV transmission: Study

Only about half of infants born to HIV-infected mothers in some African countries receive a minimum preventive dose of the drug nevirapine to help reduce the risk of mother-to-child HIV transmission, according to a study in the July 21 issue of JAMA, a theme issue on HIV/AIDS.

20 Jul 2010

International AIDS conference focuses on HIV prevention, U.S. poverty-infection link

Speeches and studies at the international HIV/AIDS conference, now underway in Vienna, were covered by a variety of news outlets.

20 Jul 2010

AIDS 2010 opens: Leaders weigh in on global HIV/AIDS funding; Clinton, Gates on efficiency

The six-day International AIDS Conference-AIDS 2010 kicked off Sunday in Vienna, Austria "amid resurgent fears that advances in the 29-year war against the disease were threatened by a slump in funding," Agence France-Presse reports.

20 Jul 2010

PSI showcases evidence-based HIV prevention methods at International AIDS Conference

Technical staff from PSI, a leading global health organization operating in more than 60 countries around the world, are currently attending the 18th International AIDS Conference in Vienna to showcase PSI's innovative, evidence-based HIV prevention methods, which have helped to successfully avert more than one billion cases of HIV infection over the past 40 years.

20 Jul 2010

A look into HIV related issues

According to a report from US health officials, the poorer neighborhoods of America's cities harbour at least 1 in 50 heterosexual adults infected with HIV. These figures are more than elsewhere in the country. According to the research team from the U.S. Centers for Disease Control and Prevention (CDC), being poor and getting HIV are linked and this was regardless of race or ethnicity.

19 Jul 2010

Today's OpEds: Public opinion and health reform; Hospitals and cost cuts; Medicare fraud 'gusher'

Less than four months after Congress approved historic health care reform legislation, the Obama administration has been making good progress in bringing some early benefits to fruition and issuing rules to guide the reform process. Despite all of the critics' hype and scare tactics, some polls suggest that the public perception of reform is slowly improving (7/18).

19 Jul 2010

First Edition: July 19, 2010

Today's headlines include the latest news regarding the politics of implementing health reform as well as developments from the international AIDS conference now underway in Vienna.

19 Jul 2010

Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine-based immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data on the Company's novel DermaVir therapeutic vaccine for HIV/AIDS during the XVIII International AIDS Conference this week in Vienna, Austria. DermaVir, the first dendritic cell-targeting topical HIV vaccine candidate, employs nanotechnology to induce multi-faceted and long-lived immune responses capable of eliminating HIV infected cells.

19 Jul 2010

ViroStatics to present VS411 Phase II dose-ranging trial data at International AIDS Conference in Vienna

ViroStatics, a US/Italian biopharmaceutical company developing innovative immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data from a randomized, dose-ranging trial of VS411, the Company's novel combination product for treating HIV/AIDS, during the XVII International AIDS Conference this week in Vienna, Austria.

19 Jul 2010

FIT Biotech to present results of FIT-06 Phase II clinical trial at XVIII International AIDS 2010 Conference

FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.

19 Jul 2010

Effective AIDS treatment but poor accessibility: Report from International AIDS conference 2010

At the 18th AIDS conference 2010 in Vienna, Julio Montaner — the President of the International AIDS Society and Chairman of the AIDS 2010 conference said this Sunday that the G-8 countries were not doing enough to ensure treatment of all people infected with HIV and AIDS. He said, “This is a very serious deficit… Let's rejoice in the fact that today we have treatments that work ... what we need is the political will to go the extra mile to deliver universal access.”

18 Jul 2010

Cash incentives cut down HIV transmission: World Bank Studies

A cash incentive has been found to lower the rates of HIV and sexually transmitted disease transmission among Malawian and Tanzanian youths revealed the World Bank, this Sunday. There were two studies undertaken to make this connection.

18 Jul 2010

New microfluidic device for effective HIV diagnosis

UC Davis biomedical engineer Prof. Alexander Revzin has developed a "lab on a chip" device for HIV testing. Revzin's microfluidic device uses antibodies to "capture" white blood cells called T cells that are affected by HIV. In addition to physically binding these cells the test detects the types and levels of inflammatory proteins (cytokines) released by the cells.

17 Jul 2010

IAS announces winners of four scientific awards to be presented at AIDS 2010

The International AIDS Society (IAS) announced today the ten winners of four prestigious scientific awards, to be presented at plenary sessions during the XVIII International AIDS Conference (AIDS 2010). Presented by the IAS and partners, these awards recognize scientists involved in innovative HIV and AIDS research throughout the world. "The quality of work represented by the 2010 awardees is remarkable," said IAS President Julio Montaner. "The IAS hopes to draw the world's attention to these individuals and to their significant scientific accomplishments, as well as to the continued need for innovation in all of the major areas of HIV and AIDS research, represented by the six conference programme tracks."

17 Jul 2010

AIDS News and Research

BC-CfE study suggests HAART may prevent transmission, spread of HIV

Cash rewards help combat STIs in rural Africa, study finds

AIDS 2010 studies, releases: Treating HIV-positive patients with ARVs drove down number of new HIV infections, study finds

International organizations mutually agree to eradicate pediatric HIV/AIDS by 2015

New microbicide gel reduces woman's risk of being infected with HIV, genital herpes

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Infants in African countries receive minimum help to reduce risk of mother-to-child HIV transmission: Study

International AIDS conference focuses on HIV prevention, U.S. poverty-infection link

AIDS 2010 opens: Leaders weigh in on global HIV/AIDS funding; Clinton, Gates on efficiency

PSI showcases evidence-based HIV prevention methods at International AIDS Conference

A look into HIV related issues

Today's OpEds: Public opinion and health reform; Hospitals and cost cuts; Medicare fraud 'gusher'

First Edition: July 19, 2010

Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference

ViroStatics to present VS411 Phase II dose-ranging trial data at International AIDS Conference in Vienna

FIT Biotech to present results of FIT-06 Phase II clinical trial at XVIII International AIDS 2010 Conference

Effective AIDS treatment but poor accessibility: Report from International AIDS conference 2010

Cash incentives cut down HIV transmission: World Bank Studies

New microfluidic device for effective HIV diagnosis

IAS announces winners of four scientific awards to be presented at AIDS 2010

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Exploring the G:Box and for high-quality imaging

Latest News